Diabetic Retinopathy Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Diabetic retinopathy is a complication of diabetes that damages the blood vessels in the retina and is a leading cause of vision impairment among working-age adults globally. The market covers anti-VEGF therapies, steroid implants, laser treatment systems, optical coherence tomography devices, and fundus cameras used in diagnosis and management. Revenues have grown from around $9.26 billion in 2025 to approximately $9.8 billion, reflecting steady demand across both developed and emerging healthcare systems.

• •Global market valued at approximately $9.8 billion in 2025
• •Includes pharmaceuticals, medical devices, and diagnostic imaging technologies
• •Projected to reach approximately $18.9 billion by 2035

The primary driver is the increasing global prevalence of diabetes, with the International Diabetes Federation estimating over 500 million adults affected worldwide, a population at risk for developing retinopathy over time. Expanded screening initiatives, particularly in primary care and community health settings, are detecting more cases at earlier, treatable stages and expanding the addressable patient population. Advances in long-acting drug delivery systems, next-generation anti-VEGF agents, and minimally invasive surgical technologies are also supporting market growth by improving treatment outcomes and patient adherence.

• •Rising global diabetes prevalence expanding the treatable patient population
• •Increasing adoption of routine diabetic retinopathy screening programs worldwide
• •Advances in sustained-release drug delivery and minimally invasive treatment technologies

The market is segmented by disease type into non-proliferative diabetic retinopathy, representing the early stage, and proliferative diabetic retinopathy, the advanced stage requiring more aggressive intervention. Treatment-based segmentation includes drugs, primarily anti-VEGF agents and corticosteroids, and devices such as laser photocoagulation systems, diagnostic cameras, and OCT imaging equipment. North America holds the largest market share due to high diabetes prevalence and advanced healthcare infrastructure, while Europe follows closely; Asia-Pacific is expected to grow at the fastest rate driven by improving healthcare access, rising disease burden, and growing screening adoption.

• •Primary segmentation: non-proliferative versus proliferative diabetic retinopathy
• •Treatment segments: pharmaceuticals including anti-VEGF and steroids, plus devices and diagnostics
• •North America leads; Asia-Pacific is the fastest-growing regional market

What are the recent trends and outlook?

Artificial intelligence-powered screening tools are gaining traction, enabling automated detection of diabetic retinopathy from retinal images with high accuracy, particularly in underserved areas with limited access to ophthalmologists. Sustained-release drug delivery systems, including injectable and implantable devices, are advancing through clinical development and could reduce treatment burden by extending dosing intervals. Gene therapy and novel molecular targets are being explored in preclinical and early clinical studies, though these remain further from market adoption. The market outlook through 2035 remains positive, supported by ongoing investments in research and development, expanding national screening programs, and the continuously growing global diabetic population.

• •Adoption of artificial intelligence for automated diabetic retinopathy screening and diagnosis
• •Development of sustained-release implants and novel drug delivery platforms
• •Market projected to continue steady growth through 2035, driven by R&D and global screening expansion